

Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2

Jan R. Brants^a, Torik A.Y. Ayoubi^b, Kiran Chada^c, Kathleen Marchal^d,
Wim J.M. Van de Ven^{a,*}, Marleen M.R. Petit^{a,1}

^aLaboratory for Molecular Oncology, Department of Human Genetics, University of Leuven and Flanders Interuniversity Institute for Biotechnology (VIB), Herestraat 49, B-3000 Leuven, Belgium

^bGenome Center Maastricht (CARIM/NUTRIM), Department of Population Genetics, Genomics and Bioinformatics, University of Maastricht, Universiteitssingel 50, 6200 MD Maastricht, The Netherlands

^cDepartment of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 675 Hoes Lane, Piscataway, NJ 08854, USA

^dESAT-SCD, University of Leuven, Kasteelpark Arenberg 10, B-3000 Leuven, Belgium

Received 24 March 2004; revised 12 May 2004; accepted 17 May 2004

Available online 15 June 2004

Edited by Lukas Huber

Abstract The developmentally regulated architectural transcription factor, high mobility group A2 (HMGA2), is involved in growth regulation and plays an important role in embryogenesis and tumorigenesis. Little is known, however, about its downstream targets. We performed a search for genes of which expression is strongly altered during embryonic development in two HMGA2-deficient mouse strains, which display a pygmy-phenotype, as compared to wild-type mice. We found that the insulin-like growth factor II mRNA-binding protein 2 gene (*IMP2*), but not its family members *IMP1* and *IMP3*, was robustly downregulated in mutant E12.5 embryos. Furthermore, we show that wild-type HMGA2 and its tumor-specific truncated form have opposite effects on *IMP2* expression. Our results clearly indicate that HMGA2 differentially regulates expression of *IMP* family members during embryogenesis.

© 2004 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.

Keywords: Coding region determinant-binding protein; High mobility group A1; Insulin-like growth factor II; hnRNP K homology-domain containing protein overexpressed in cancer; p62; VICKZ

1. Introduction

High mobility group A2 (*HMGA2*) is a member of the HMGA gene family [1,2]. The HMGA proteins contain three DNA-binding domains, AT-hooks, which interact with AT-

rich stretches in the narrow minor groove of DNA [3], and an acidic C-terminal tail. Although these proteins possess a classical transcription factor structure, they do not have transcriptional activation capacity by themselves. HMGA proteins play a critical role in organizing the assembly and stabilization of nucleo-protein transcriptional complexes (enhanceosomes) at the level of enhancer- or promoter-regions, resulting in induction or repression of transcription. They are classified as architectural transcription factors (reviewed in [4,5]). The best characterized example of how HMGA proteins can modulate gene expression is provided by studies describing the expression regulation of the interferon- β gene [6]. Recently, it was shown that HMGA2 modulates the promoter activity of the DNA repair gene *ERCC1* [7] and of the cyclin A gene [8].

In mice, HMGA2 expression is high during early development but barely detectable in adult tissues [9]. Consistent with its growth-regulatory role is the pygmy phenotype in mice in which the *HMGA2* gene is homozygously inactivated [10]. *HMGA2* is disrupted and aberrantly expressed in many tumor types making this gene probably the most frequently rearranged gene in human neoplasias (reviewed in [11,12]). We identified the *HMGA2* gene as the gene that is disrupted by 12q15 chromosomal rearrangements observed in a variety of commonly occurring benign solid tumors [13,14]. Disruption of the gene in these tumors usually results in the expression of a truncated protein only containing the DNA-binding domains of wild-type HMGA2. In contrast to the expression of aberrant forms of HMGA2 in benign tumors, overexpression of wild-type HMGA2 has been reported in various malignant tumors, such as breast cancer [15] and pancreatic tumors [16].

Although HMGA2 has been clearly implicated in cell proliferation and tumorigenesis, the underlying molecular and biological events involved in these phenomena still need further unraveling. One way to address this issue is to search for genes of which the expression is regulated by this architectural transcription factor, such as recently described for the structurally related *HMGA1* gene [17]. We have performed expression profiling experiments using embryos of the spontaneous *pg/pg* mouse mutant, which is *HMGA2*-deficient, and corresponding

* Corresponding author. Fax: +32-16-34-60-73.

E-mail address: wim.vandeven@med.kuleuven.ac.be (W.J.M. Van de Ven).

¹ M.M.R. Petit is a postdoctoral fellow of the Fund for Scientific Research, Flanders, Belgium (F.W.O. – Vlaanderen).

Abbreviations: HMGA, high mobility group A; IMP, insulin-like growth factor II mRNA-binding protein; BLAST, basic local alignment search tool; NCBI, National Center for Biotechnology Information; KH, hnRNP K homology; IGF-II, insulin-like growth factor II; RRM, RNA recognition motif

wild-type mouse embryos, and report on the differential impact of HMGA2 on the expression of the genes encoding the various members of the insulin-like growth factor II (IGF-II) mRNA-binding protein (IMP) family. We have validated our results using the genetically engineered *HMGA2*-specific knockout mouse strain and a cell-based system.

2. Materials and methods

2.1. Mouse strains and genotyping

Mouse strains included C3Wf.Cg-*Hmga2*^{pg/BmJ} (Jackson Laboratories), which is a spontaneous *pg/pg* mutant, and C57BL-129SV in which the *HMGA2* allele was inactivated by gene targeting [10]. *HMGA2*-genotyping was performed as described in [18].

2.2. RNA extraction and Northern blot analysis

Total RNA was isolated from whole mouse embryos using the guanidine isothiocyanate method [19]. RNA from NIH/3T3 cells was isolated using the RNeasy total RNA isolation kit (Qiagen), according to the manufacturer's conditions. Northern blot analysis was performed as described in [20]. After exposure to a PhosphorImager screen (Molecular Dynamics), signals were detected using a Typhoon 9200 scanner (Amersham Biosciences) and quantified using ImageQuant 5.2 software (Molecular Dynamics).

2.3. Microarray analysis

Microarray analysis was performed at the VIB MicroArray Facility (www.microarrays.be). Arrays with ArrayExpress Accession Nos. A-MEXP-4 and A-MEXP-6 (www.ebi.ac.uk/arrayexpress/) were hybridized with pooled RNAs from 10 E12.5 *pg/pg* or 10 corresponding wild-type mouse embryos, as molecular probes. Antisense RNA was amplified using a modified protocol of *in vitro* transcription as described [21]. Cy3 and Cy5 labeling protocols were done as described (P-MEXP-578 and P-MEXP-579). Hybridization and scanning of the slides was performed as described (P-MEXP-580 and P-MEXP-582). For image analysis, ArrayVision was used (Imaging Research Inc). Spot intensities were measured as artifact-removed total intensities (ARVol) subtracted with median intensity of the local background of each spot. For each gene, ratios of red (Cy-5) over green (Cy-3) intensities (I) were calculated and normalized via a running median of the log₁₀ ratios (log₁₀ (ICy-5/ICy-3)) over the log₁₀ total intensity (log₁₀ (ICy-5 * ICy-3)). Mean ratios were calculated from the duplicate spots and represented as average non-logarithmic ratios in the results. Statistical analysis was performed as described in [22].

2.4. Primers

The following primers were used: IMP1up1: 5'-GTAGAAA-GTTTGGCGCTC-3'; IMP1up2: 5'-GACTACGAATTCACCAT-GAACAAGCTTTACATCGGCAAC-3'; IMP1low1: 5'-TATCTTG-GAGCCAATGGGAC-3'; IMP1low2: 5'-CTGATGGCGGCCGCT-CACTTCCTCCGAGCCTG-3'; IMP2up1: 5'-CTCTCGGGAAG-AC-3'; IMP2up2: 5'-GACTACGAATTCGGGATGATGAACAAG-CTGTAC-3'; IMP2low1: 5'-TCAGGTGTTGGGAGGGCTAC-3'; IMP2low2: 5'-CTGATGGCGGCCGCTCACTTGCTGCGCTGTG-3'; IMP3up3: 5'-TCCAGAGTTTATCAAGTGCTG-3'; IMP3up5: 5'-GACTACGAATTCGGTGACCAGACACCTGATGAG-3'; IMP3low3: 5'-CTTCCCTTAGGTTATCCATG-3'; IMP3low5: 5'-CTG-ATGGCGGCCGACAGGAGACAACAGCTCTTC-3'; HMGA2-up3: 5'-GACTACAGATCTAGGCAGGATGAGCGCACG-3'; HMGA2low3: 5'-GTAGTCGAATTCGGTAGAAATCGAACGTTGC-G-3'; HMGA2low5: 5'-GTAGTCGAATTCCTTACCATTTCCTAGG-TCTGCCTC-3'; actin-up: 5'-ACTATTGGCAACGAGCGGTTC-3'; and actin-low: 5'-GGAGCCACCGATCCACACAGA-3'.

2.5. Plasmids

Mouse *IMP1* and *IMP2* open reading frames, and part of the 3'-UTR of *IMP3* were generated by nested RT-PCR from E12.5 mouse embryonic RNA using the SuperscriptTM First-Strand system (Invitrogen), according to the conditions of the manufacturer. PCR-primer sets: IMP1up1/IMP1low1, IMP2up1/IMP2low1 and IMP3up3/IMP3low3. Nested primer sets: IMP1up2/IMP1low2, IMP2up2/IMP2low2 and IMP3up5/IMP3low5. The *IMP1* and *IMP2* PCR-products

were ligated into pcDNA3.1/His (Invitrogen) (plasmids pJB19 and pJB20). The *IMP3*-PCR-product was inserted into pcDNA3 (Invitrogen) (pJB24).

Wild-type *HMGA2* and *HMGA2Tr* were generated by PCR from the coding sequence of human *HMGA2* as template using Pwo DNA polymerase (Roche) according to the conditions of the manufacturer. Primer sets: HMGA2up3/HMGA2low3 and HMGA2up3/HMGA2low5. The amplified DNA fragments were inserted into the retroviral pMSCVpuro vector (Clontech) [23] (plasmids pJB13 and pJB15).

2.6. Hybridization probes and labeling

The *IMP2* 3'-UTR-specific probe (position 1063–1606 bp behind the stop codon) was obtained by digestion of AW542316. The *IMP3* 3'-UTR-specific probe was obtained by digestion of pJB24. The *IMP1*- and *HMGA2* CDS-specific probes were generated by digestion of pJB19 and pJB13, respectively. The mouse β -actin probe was obtained by PCR with primers Actin-up and Actin-low on E12.5 embryonic cDNA. Probes were labeled with [α -³²P]dCTP using the megaprime DNA labeling system (Amersham) according to the manufacturer's conditions.

2.7. Cell culture, generation of retrovirally transduced NIH/3T3 cells

Cell lines included 293T (ATCC CRL-1573 human embryonic kidney epithelial cells expressing SV40 T-antigen) and NIH/3T3 (mouse embryo fibroblast cells; ATCC CRL-1658). Cells were grown as described [24]. Retrovirally transduced NIH/3T3 cell lines were obtained as described in [25].

2.8. Antibody generation, SDS-PAGE and Western blotting

Polyclonal rabbit antiserum HMGA2fix was raised against a mixture of three synthetic peptides: ³ARGEGAGQPSTSAQQQPAAPAPQ KR²⁷, ⁵⁹SPSKAAQKKAEATGEKR⁷⁵ and ⁸⁰PRKWPOQVQKKP AQEE⁹⁶, synthesized as multiple-antigen peptide conjugates (Research Genetics). Expression of HMGA2 and HMGA2Tr in recombinant retrovirus transduced NIH/3T3 cells was verified by SDS-PAGE and Western blotting as described [24], using HMGA2fix antibody.

3. Results and discussion

3.1. Identification of *HMGA2* downstream target genes with strongly downregulated expression in *HMGA2*-deficient embryos

To identify highly downregulated downstream target genes of *HMGA2*, we initially compared by microarray analysis the gene expression profile in embryos of the spontaneous *pg/pg* mouse strain, which can be considered as a *HMGA2* null mutant strain, to that in corresponding wild-type embryos. The developmentally regulated *HMGA2* gene is only expressed during embryogenesis and since its expression is readily detected from stage E10.5 to stage E13.5 and decreases dramatically thereafter [9], we used RNA from whole embryos of stage E12.5 in microarray analysis. One of the 8600 genes on the microarray slides was *HMGA2*, represented by a clone with GenBank Accession No. AW550862, which was considered as an internal, positive control. The microarray hybridization was performed a second time in a color flip experiment.

The results of the microarray experiments revealed many differentially expressed genes. As expected, the ratio between the measured signal for *HMGA2* (AW550862) in wild-type- and the spontaneous *pg/pg* mutant embryos was high (Table 1). To narrow down the list of differentially expressed genes in the datasets, we selected those clones that had a signal ratio comparable to that of the positive control AW550862. This selection resulted in three additional clones (Table 1), AW548319 and AW542316, and an as yet not annotated clone. All other differentially regulated genes displayed only a minor difference in expression levels and are therefore not included in this study.

Table 1
Transcripts downregulated to the same extent as HMGA2 in E12.5 pg/pg mouse embryos

GenBank No.	Gene description	WT/pg ratio	WT/pg ratio color flip	WT/pg ratio average
AW550862	Hmga2	71.42	80.04	75.73
AW548319	Hmga2	56.61	71.56	64.08
Unknown	Hmga2	19.25	41.44	30.34
AW542316	Imp2	31.37	51.61	41.49

After sequencing the selected clones, basic local alignment search tool (BLAST) searches revealed that the not yet annotated clone and AW548319 both corresponded to *HMGA2*. The nucleotide sequence of the third clone, AW542316, was similar to sequences of the 3'-UTR of the human *IMP2* gene, indicating that AW542316 might correspond to the gene encoding mouse *IMP2*.

3.2. Downregulated clone AW542316 corresponds to mouse *IMP2*

To establish that AW542316 indeed corresponds to mouse *IMP2*, the complete mouse *IMP2* cDNA sequence had to be isolated, since at the time of our investigations, the contiguous mouse *IMP2* cDNA sequence was not yet available in the public databases. Using the mouse EST database of the NCBI (National Center for Biotechnology Information), a contig could be generated covering the complete putative *mIMP2* cDNA sequence containing part of the 5'-UTR, the open reading frame, the complete 3'-UTR, including the AW542316 sequences, and the poly(A)-tail. Subsequently, the complete mouse *IMP2* open reading frame was cloned by RT-PCR using E12.5 mouse embryonic RNA with *mIMP2*-specific primers, sequenced, and its nucleotide sequence was submitted to NCBI database (GenBank Accession No.: AY531659). Translation of the open reading frame revealed an amino acid sequence that indeed resembled most closely (about 94% sequence identity) the sequence of human *IMP2* (Fig. 1A and B). In conclusion, results of our studies so far clearly establish that it is *IMP2* that is downregulated in E12.5 embryos of the *pg/pg* mouse mutant strain.

IMP2 belongs to a family of three IGF-II mRNA binding proteins (*IMP1*, *IMP2* and *IMP3*), which were found during a search for *trans*-acting factors associating with IGF-II mRNAs. Structurally, the *IMP* proteins are highly similar, containing the unique combination of six characteristic RNA-binding modules, two RNA recognition motifs (RRMs) [26] and four hnRNP K homology (KH) domains [27] (Fig. 1). *IMP1* is orthologous to the chicken zipcode-binding protein [28] and to the mouse c-myc coding region determinant-binding protein. *IMP3* is identical to the KH-domain containing protein overexpressed in cancer [29] and is orthologous to the Vera protein in *Xenopus laevis* oocytes [30].

A splice variant of human *IMP2*, p62, missing 43 amino acids located between KH-domains 2 and 3, was identified as an autoantigen in human hepatocellular carcinoma [31]. RT-PCR analysis (data not shown) indicated that the observed downregulation of *IMP2* expression in *pg/pg* mutant embryos concerns only the *IMP2* transcript, since the p62 transcript could not be detected in wild-type E12.5 mouse embryos.

3.3. Differential downregulation of *IMP* family members in E12.5 *pg/pg* mouse embryos

To confirm the microarray results, we performed Northern blot analysis of RNA isolated from *pg/pg* and corresponding

wild-type mouse embryos. As expected, *HMGA2* expression was detected in wild-type but not in the *pg/pg* embryos (Fig. 2A). Furthermore, *IMP2* expression appeared to be beyond the detection level in the *pg/pg* embryos, whereas it was clearly detectable in the wild-type embryos (Fig. 2A). Similar Northern blot analysis using *IMP1*- or *IMP3*-specific probes showed no detectable differences in *IMP1* or *IMP3* expression levels in *pg/pg* embryos as compared to wild-type embryos (Fig. 2B), establishing that only the expression of the *IMP2* member of this gene family is affected in *pg/pg* embryos. Finally, Northern blot analysis of RNA isolated from *pg/pg* and corresponding wild-type newborn mice of 10 days old revealed expression of low, but comparable, levels of *IMP2* transcripts in both strains. *HMGA2* expression was clearly reduced in the wild-type pups (data not shown).

3.4. *IMP2* is a downstream target of *HMGA2*

A remaining issue pertains to the question whether *IMP2* is a downstream target of *HMGA2*. Genetically, the *pg/pg* mouse is only partially characterized. A genomic region on chromosome 10 of more than 56 kb, encompassing the 5' sequences and the first two exons of *HMGA2*, is deleted [10]. To exclude the possibility that the reason for *IMP2* expression not being detectable in Northern blot analyses is due to the fact that *IMP2* maps closely to *HMGA2*, and might therefore also be deleted in *pg/pg* mice, the chromosomal mapping position of *IMP2* was determined. Mouse BLAST-Like Alignment Tool search of the open reading frame of *IMP2* against the UCSC (University of California, Santa Cruz) Genome Browser revealed, however, that the mouse *IMP2* gene is located on chromosome 16. The possibility still cannot be excluded that *IMP2* expression is regulated by another gene mapping to the deleted region in *pg/pg* mice. To resolve this issue, we studied *IMP2* expression in *HMGA2* null mutant mice generated via targeted disruption of the *HMGA2* gene [10]. Northern blot analysis of RNA isolated from E12.5 *HMGA2*^{-/-}, *HMGA2*^{+/-}, and *HMGA2*^{+/+} embryos revealed that no *HMGA2* and very low levels of *IMP2* transcripts could be detected in the *HMGA2*^{-/-} embryos (Fig. 3). In the *HMGA2*^{+/-} embryos, both *HMGA2* and *IMP2* expression levels were clearly reduced as compared to the levels observed in *HMGA2*^{+/+} embryos (Fig. 3). No differences in expression levels of the *IMP2* family members, *IMP1* and *IMP3*, could be observed by performing similar Northern blot analysis (Fig. 3), clearly revealing a differential regulation control within the *IMP* family during embryogenesis.

These results point towards a prominent role for *HMGA2* in the regulation of *IMP2* expression. Expression of *IMP2* is biphasic with an early expression in oocytes and in the zygote, and a sharp increase in expression around embryonic day E12.5, which declines towards birth [30]. In this respect, *HMGA2* and *IMP2* display a somewhat similar expression profile during mouse embryogenesis. Our data, showing that




Fig. 1. Amino acid alignment of mouse IMP2 with all human IMP-family members. (A) Protein sequence alignment of hIMP1, hIMP2, hIMP3 and mlmp2. The alignment was made using AlignX, a component of Vector NTI suite 8.0 software (InforMax, Inc). Amino acids identical to the ones in mlmp2 are shown in gray. The two RRM and four KH-domains are underlined [30]. (B) % Amino acid (AA) identity between all human and mouse IMP-family members. Identity was calculated with AlignX.

IMP2 expression was drastically downregulated in E12.5 *HMG2*^{-/-} mice, indicate that *HMG2* is very likely to be required for the sharp increase in expression of *IMP2* at E12.5. We have to note here that a very faint *IMP2* signal was still detected by Northern blot analysis of RNA isolated from E12.5 *HMG2*^{-/-} mice (Fig. 3), indicating that very low ex-

pression levels of *IMP2* are still present in E12.5 *HMG2*^{-/-} mice. These data indicate that, although *HMG2* plays a prominent role in the regulation of *IMP2*-expression, other factors must be involved too.

Functionally, the IMP proteins are capable of strong and specific RNA-binding, and because of this, they have been




Fig. 2. Differential expression of IMP-family members in E12.5 pygmy embryos. Northern blots, made with total RNA isolated from whole E12.5 homozygous pygmy embryos and wild-type siblings, were hybridized with an IMP2-specific 3'-UTR probe (A), an HMGA2-specific coding region probe (A), an IMP1-specific coding region probe (B), or an IMP3-specific 3'-UTR probe (B). The lower panel in each figure shows rehybridization of the blots with a β -actin probe as control for equal RNA-loading.




Fig. 3. IMP2 is a downstream target of HMGA2. Northern blots, made with total RNA isolated from whole E12.5 *HMGA2*^{-/-}, *HMGA2*^{+/-} and *HMGA2*^{+/+} siblings, were hybridized with IMP2- or IMP3-specific 3'-UTR probes, or with HMGA2- or IMP1-specific coding region probes. The lower panel shows rehybridization of the blots with a β -actin probe as control for equal RNA-loading.

implicated in post-transcriptional processes such as mRNA localization, turnover and translational control. The three human IMP proteins have been shown to specifically bind to

IGF-II leader 3 mRNA (5'-UTR), where they have an influence on the translation of the mRNA into protein [30], and to the 3' region of H19 RNA. To look whether Imp2 is involved in the turnover of these RNAs, we looked for the expression levels of *Igf2* and *H19* in the microarray dataset. However, microarray analysis did not reveal a significant change in expression levels of these genes.

Different studies implicated the IMP proteins in temporal and spatial control of gene expression at the level of mRNA rather than at the level of gene transcription. In this regard, it is tempting to speculate that the effect of HMGA2 on cell proliferation during embryonic development and tumorigenesis possibly involves IMP2. This also suggests that strong downregulation of IMP2 expression at E12.5 in mice may contribute to a pygmy phenotype.

Since IMP2 is drastically downregulated to nearly undetectable levels in the E12.5 pygmy and *HMGA2*^{-/-}-mice, an *IMP2* knockout mouse would further clarify the importance of *IMP2* deficiency in the *HMGA2*^{-/-}-phenotype. Because of the drastic downregulation of IMP2 in the HMGA2 knockout models, we could predict a similar growth retarded phenotype for the *IMP2*^{-/-} mouse, pointing to a very important role of the HMGA2-IMP2 pathway in embryonic development. In this regard, it is interesting to note that the recently published *Imp1*-deficient mice were on an average 40% smaller than wild-type and heterozygous sex-matched littermates [32].

At present, not much is known about possible differences in the function of the three IMP proteins. They are expressed in the same time frame during embryonic development and since it was shown that their major functions are carried out by the phylogenetically conserved KH-domains [33], one could assume that there is functional redundancy between the IMP family members. However, from the observed differential regulation during embryogenesis reported here, a first indication seems to emerge, pointing towards functional differentiation.

3.5. Effect of a tumor-related aberrant form of HMGA2 on IMP2 expression

With respect to tumorigenesis, the IMP proteins share various characteristics with HMGA2. They all are oncofetal proteins that are highly expressed during embryonic development, silenced during adult life, and misexpressed in different kinds of neoplasias [34]. Certain benign tumors are characterized by chromosomal aberrations involving the *HMGA2* gene [13,14]. Many of these tumors express a truncated form of HMGA2 (HMGA2Tr), only containing the three DNA binding domains and lacking the acidic and spacer domains (Fig. 4A). Such a HMGA2Tr induces neoplastic transformation of NIH/3T3 murine fibroblasts [35]. Transgenic mice aberrantly expressing this truncated HMGA2 protein present gigantism that is associated with lipomatosis [36], develop adiposity, and display an abnormal high prevalence of lipomas [37]. To study the effect of HMGA2Tr on *IMP2*, NIH/3T3 cell lines overexpressing HMGA2 or HMGA2Tr were made by retroviral transduction. Expression of HMGA2 and HMGA2Tr was assayed by Western blot analysis with an HMGA2-specific antibody (Fig. 4B, lanes 2 and 3). *IMP2* expression levels were determined by Northern blot analysis. In Fig. 4C and D, it is shown that HMGA2 upregulates *IMP2* expression and this to an extent of about 124% of the level in the control cells (Mock). However, HMGA2Tr appears to




Fig. 4. Effect of a tumor-specific aberrant form of HMGA2 on IMP2 expression. (A) Schematic representation of wild-type HMGA2 and its tumor-specific form HMGA2Tr (AT: AT-hook, AD: acidic domain). (B) Western blot analysis of cell lysates of NIH/3T3 stable cell lines overexpressing wild-type HMGA2 or HMGA2Tr, using the HMGA2fix antibody. (C) Representative Northern blot of RNA extracted from the NIH/3T3 stable cell lines hybridized with an IMP2-specific 3'-UTR probe. The lower panel shows rehybridization of the blot with a β -actin probe as control for equal RNA-loading. (D) Graph depicting quantification of IMP2 mRNA levels of the Northern blot analyses. The results are given as a percentage of Mock (NIH/3T3 infected with empty vector) after normalization to β -actin. The results are shown as the average of three independent experiments.

downregulate *IMP2* expression to about 36% of the level in the control cells (Mock). Similar results were obtained by comparing mRNA expression levels between HMGA2Tr-overexpressing and control NIH/3T3 cells by microarray analysis (our unpublished observations). Similar Northern blot analysis with probes specific for *IMP1* and *IMP3* revealed no difference in the expression levels of these genes (results not shown).

These experiments indicate that the HMGA2Tr that is frequently expressed in benign solid tumors exerts a differential, negative effect on expression of members of the *IMP* gene family and point to the potential significance of the HMGA2-IMP2 pathway being deregulated in these tumors. Our results also suggest that the acidic tail of HMGA2 plays a role in the transcriptional regulation of target genes. Recently, Noro et al. [38] showed that the acidic tail of HMGA2 is not involved in determining the HMGA2 DNA-binding specificity, but can alter HMGA2/DNA complexes. Their results suggested that wild-type HMGA2 and HMGA2Tr could have the same target genes, but a differential regulating effect, in agreement with the results presented here. To resolve the question as to whether

the HMGA2-IMP2 pathways are involved in tumor development, IMP2 expression levels can be assessed in tumors with aberrant expression of HMGA2.

In any case, the differential effect of wild-type HMGA2 on *IMP* gene expression during mouse embryogenesis constitutes a new opening for the functional dissection of the latter gene family.

Acknowledgements: We thank Paul Van Hummelen of the VIB MicroArray Facility (www.microarrays.be) for performing the microarray analysis, and Koen Crombez for interesting discussions. This work was supported in part by GOA (Geconcerteerde Onderzoeksacties)-grant 2002/10 and by grants from the Cancer Research Program of "Fortis Verzekeringen", the Fund for Scientific Research (F.W.O. – Vlaanderen, Krediet Aan Navorsers 1.5.098.03), and the Belgian Federation against Cancer (A5890).

References

- [1] Johnson, K.R., Lehn, D.A., Elton, T.S., Barr, P.J. and Reeves, R. (1988) *J. Biol. Chem.* 263, 18338–18342.

- [2] Manfioletti, G. et al. (1991) *Nucleic Acids Res.* 19, 6793–6797.
- [3] Reeves, R. and Nissen, M.S. (1990) *J. Biol. Chem.* 265, 8573–8582.
- [4] Reeves, R. (2001) *Gene* 277, 63–81.
- [5] Reeves, R. and Beckerbauer, L. (2001) *Biochim. Biophys. Acta* 1519, 13–29.
- [6] Munshi, N., Agaloti, T., Lomvardas, S., Merika, M., Chen, G. and Thanos, D. (2001) *Science* 293, 1133–1136.
- [7] Borrmann, L., Schwanbeck, R., Heyduk, T., Seebeck, B., Rogalla, P., Bullerdiek, J. and Wisniewski, J.R. (2003) *Nucleic Acids Res.* 31, 6841–6851.
- [8] Tessari, M.A. et al. (2003) *Mol. Cell. Biol.* 23, 9104–9116.
- [9] Zhou, X., Benson, K.F., Przybysz, K., Liu, J., Hou, Y., Cherath, L. and Chada, K. (1996) *Nucleic Acids Res.* 24, 4071–4077.
- [10] Zhou, X., Benson, K.F., Ashar, H.R. and Chada, K. (1995) *Nature* 376, 771–774.
- [11] Hess, J.L. (1998) *Am. J. Clin. Pathol.* 109, 251–261.
- [12] Tallini, G. and Dal Cin, P. (1999) *Adv. Anat. Pathol.* 6, 237–246.
- [13] Ashar, H.R., Fejzo, M.S., Tkachenko, A., Zhou, X., Fletcher, J.A., Weremowicz, S., Morton, C.C. and Chada, K. (1995) *Cell* 82, 57–65.
- [14] Schoenmakers, E.F., Wanschura, S., Mols, R., Bullerdiek, J., Van den Berghe, H. and Van de Ven, W.J. (1995) *Nat. Genet.* 10, 436–444.
- [15] Rogalla, P., Drechsler, K., Kazmierczak, B., Rippe, V., Bonk, U. and Bullerdiek, J. (1997) *Mol. Carcinog.* 19, 153–156.
- [16] Abe, N. et al. (2003) *Br. J. Cancer* 89, 2104–2109.
- [17] Treff, N.R., Pouchnik, D., Dement, G.A., Britt, R.L. and Reeves, R. (2004) *Oncogene* 23, 777–785.
- [18] Anand, A. and Chada, K. (2000) *Nat. Genet.* 24, 377–380.
- [19] Ausubel, F.M. (1995) *Current protocols in molecular biology*, Wiley, New York, NY.
- [20] Ayoubi, T.A., Jansen, E., Meulemans, S.M. and Van de Ven, W.J. (1999) *Oncogene* 18, 5076–5087.
- [21] Puskas, L.G., Zvara, A., Hackler Jr., L. and Van Hummelen, P. (2002) *Biotechniques* 32, 1330–1334, 1336, 1338, 1340.
- [22] Marchal, K., Engelen, K., De Brabanter, J., Aerts, S., De Moor, B., Ayoubi, T. and Van Hummelen, P. (2002) *J. Biol. Syst.* 10, 409–430.
- [23] Hawley, R.G., Lieu, F.H., Fong, A.Z. and Hawley, T.S. (1994) *Gene Ther.* 1, 136–138.
- [24] Petit, M.M., Meulemans, S.M. and Van de Ven, W.J. (2003) *J. Biol. Chem.* 278, 2157–2168.
- [25] Hensen, K., Van Valckenborgh, I.C., Kas, K., Van de Ven, W.J. and Voz, M.L. (2002) *Cancer Res.* 62, 1510–1517.
- [26] Query, C.C., Bentley, R.C. and Keene, J.D. (1989) *Cell* 57, 89–101.
- [27] Siomi, H., Choi, M., Siomi, M.C., Nussbaum, R.L. and Dreyfuss, G. (1994) *Cell* 77, 33–39.
- [28] Ross, A.F., Oleynikov, Y., Kislauskis, E.H., Taneja, K.L. and Singer, R.H. (1997) *Mol. Cell. Biol.* 17, 2158–2165.
- [29] Mueller-Pillasch, F. et al. (1997) *Oncogene* 14, 2729–2733.
- [30] Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A.H., Wewer, U.M. and Nielsen, F.C. (1999) *Mol. Cell. Biol.* 19, 1262–1270.
- [31] Zhang, J.Y., Chan, E.K., Peng, X.X. and Tan, E.M. (1999) *J. Exp. Med.* 189, 1101–1110.
- [32] Hansen, T.V., Hammer, N.A., Nielsen, J., Madsen, M., Dalbaeck, C., Wewer, U.M., Christiansen, J. and Nielsen, F.C. (2004) *Mol. Cell. Biol.* 24, 4448–4464.
- [33] Nielsen, F.C., Nielsen, J. and Christiansen, J. (2001) *Scand. J. Clin. Lab. Invest Suppl.* 234, 93–99.
- [34] Yaniv, K. and Yisraeli, J.K. (2002) *Gene* 287, 49–54.
- [35] Fedele, M. et al. (1998) *Oncogene* 17, 413–418.
- [36] Battista, S. et al. (1999) *Cancer Res.* 59, 4793–4797.
- [37] Arlotta, P., Tai, A.K., Manfioletti, G., Clifford, C., Jay, G. and Ono, S.J. (2000) *J. Biol. Chem.* 275, 14394–14400.
- [38] Noro, B. et al. (2003) *Biochemistry* 42, 4569–4577.